The race to develop biosimilar or follow-on biologic entrants in the U.S. insulin market has suffered from a fundamental strategic flaw: chasing the largest top-line market size rather than recognizing completely vacant commercial spaces. For a decade, developers viewed Sanofi's Lantus (insulin glargine) as the ultimate prize simply because it was the highest-grossing basal insulin.
The Mirage of Market Share vs. Reality
Market share looks large—until you see how many players are fighting for each molecule
The subsequent chronology illustrates how rapidly this singular focus led to an overcrowded market. On December 16, 2015, the FDA approved Lilly's Basaglar as a follow-on biologic under a pathway that's since been discontinued (the molecule remains for sale) https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/205692Orig1s000ltr.pdf. Years later, on July 28, 2021, the FDA approved Viatris [fka Mylan]/Biocon's Semglee as the first interchangeable biosimilar to Lantus https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/761201Orig1s000ltr.pdf, followed quickly on December 17, 2021, by Lilly's Rezvoglar https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761215Orig1s000Approv.pdf—marking Lilly's transition to the new FDA 351(k) biologic pathway.
To defend its market share, Sanofi introduced an unbranded glargine via its Winthrop unit on June 30, 2022 https://blog.sstrumello.com/2022/06/sanofi-joins-ranks-of-35vial-insulin.html. However, after a Medicaid rebate cap elimination took effect on January 1, 2024 https://www.kff.org/medicaid/what-are-the-implications-of-the-recent-elimination-of-the-medicaid-prescription-drug-rebate-cap/, Sanofi slashed branded Lantus's list price by 78% https://www.globenewswire.com/news-release/2023/03/16/2629188/0/en/Press-Release-Sanofi-cuts-U-S-list-price-of-Lantus-its-most-prescribed-insulin-by-78-and-caps-out-of-pocket-Lantus-costs-at-35-for-all-patients-with-commercial-insurance.html. Historical pricing data tracked by 46brooklyn Research https://www.46brooklyn.com/branddrug-boxscore/ (free for anyone to use) confirms these cuts, which ultimately made unbranded versions redundant; Winthrop discontinued its unbranded glargine on March 31, 2026 https://healthprovidersdata.com/hipaa/codes/NDC_0955-1729.aspx. Mirroring this shift, Novo Nordisk similarly halted its unbranded fast-acting and basal lines, while Lilly's unbranded Humalog remains a rare exception because it outsells its branded counterpart in the U.S. at the moment.
Despite this hyper-saturation, white-label arrangements like CivicaScript and CalRx continue to emerge, and on May 4, 2026, Lannett Company, Lanexa Biologics, and Sunshine Lake Pharma announced the FDA approval of LANGLARA as yet another interchangeable biosimilar https://www.businesswire.com/news/home/20260504761789/en/Lannett-Company-Lanexa-Biologics-and-Sunshine-Lake-Pharma-announce-FDA-Approval-of-LANGLARA-an-Interchangeable-Biosimilar-of-Lantus-insulin-glargine/. With additional glargine pipeline entrants from Sandoz/Gan & Lee, Amphastar Pharmaceuticals/ANP, and Meitheal Pharmaceuticals/THDB all awaiting FDA approval decisions on their glargine biosimilar products in the foreseeable future, this crowded environment has forced deflationary pricing pressure and razor-thin margins. While this delivered a victory for PBM rebate-driven formularies, it hollowed out the commercial return for manufacturers and turned glargine into a low-priced commodity.
Meanwhile, a much more lucrative opportunity went completely unnoticed.
When I first learned that Levemir would be discontinued, my immediate reaction was simple:
"Again?! How many fµcking times will patients be forced to endure such egregious business practices?"
When Novo Nordisk announced it would discontinue Levemir (insulin detemir) to prioritize manufacturing capacity for its high-margin GLP-1 weight-loss drugs, corporate narratives implied falling demand. However, publicly available data suggested otherwise. Data derived from the federal government's Medical Expenditure Panel Survey (MEPS), conducted by the Agency for Healthcare Research and Quality (AHRQ) https://meps.ahrq.gov/mepsweb/, showed that prescriptions for Levemir remained remarkably consistent over time. To analyze this underlying MEPS data, pharmacists and pharmacy technicians frequently rely on ClinCalc's DrugStats database https://clincalc.com/DrugStats/. According to those figures, Levemir ranked as the 117th bestselling drug in the U.S., accounting for 5,214,067 prescription fills dispensed to 1,027,442 unique patients. Furthermore, reporting from diaTribe News https://diatribe.org/diabetes-medications/levemir-long-acting-insulin-be-discontinued-novo-nordisk indicates that Levemir generated nearly $650 million in revenue for Novo Nordisk during 2022.
Walking away from this massive, completely uncontested 10% slice of the U.S. insulin volume leaves a commercial vacuum wide open to any developer willing to step in. This is not just another commodity; it is a clinical necessity serving specific patient populations that cannot simply non-medically switch to glargine or degludec. Levemir remains a distinct clinical tool as the only basal option with an FDA label for use during pregnancy, and the only one whose formulation allows it to be safely diluted for infants and highly insulin-sensitive patients.
Historically, when a manufacturer discontinued an insulin—such as Lilly Iletin animal-source pork insulin, or Lilly's Humulin U (Ultralente)—left patients had no recourse because the legal framework did not exist to replicate them.
Today, a viable legal playbook is firmly in place. Under the Biologics Price Competition and Innovation Act (BPCIA) and the FDA's subsequent transition of insulin to a biologic pathway https://www.fda.gov/drugs/biosimilars/deemed-be-license-provision-features-and-benefits, developers have a clear, defined 351(k) approval route to bring an abandoned molecule back to market. This structural transition is underscored by the FDA announcement at https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-agencys-continued-efforts-bring-competition-insulin/ mapping out the agency's more modern framework to streamline generic competition for biological drug products.
Recognizing this shift, the Alliance to Protect Insulin Choice https://alliancetoprotectinsulinchoice.org/ and patient advocates are rewriting the script. By highlighting these unique U.S. market dynamics and shifting PBM drug channels, advocacy is no longer just pleading for access—it is handing developers a highly predictable, zero-competition economic opportunity. The most lucrative biosimilar insulin opportunity in America isn't necessarily the biggest selling innovator molecule; it's the one everyone else abandoned.
No comments:
Post a Comment